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Thyroid hormones play important roles in 
regulating metabolism, growth, and develop­
ment, especially in normal brain maturation 
and development (Porterfield and Hendrich 
1993). They regulate the processes of neuro­
genesis, denditric and axonal growth, synap­
togenesis, and myelination (Bernal 2007). It is 
now recognized that even slight differences in 
the concentration of thyroid hormones dur­
ing pregnancy or after delivery may be associ­
ated with neurological impairment (Freire 
et al. 2010; Pop et al. 1999). Thyroid hor­
mones are also essential for children because 
some neurodevelopmental processes, such as 
myelination, are not completed until adoles­
cence (Rice and Barone 2000), and they are 
also important for the behavior and cognitive 
function of the young and adolescent brain 
(Anderson 2001). In addition, thyroid hor­
mone deficiency causes growth delay, preco­
cious puberty in both sexes, and hirsutism in 
females (Papi et al. 2007).
There is a growing concern that environ­
mental toxicants may be related to thyroid 
impairment (Boas et al. 2009). Animal stud­
ies have suggested that exposure to some 
perfluoroalkyl acids (PFAAs), including 
perfluorooctanoate (PFOA, also called C8), 
perfluorooctane sulfonate (PFOS), and per­
fluorononanoic acid (PFNA), may interfere 
with thyroid status (Lau et al. 2007; Liu et al. 
2011). There had been some concern that 
these apparent associations may derive from 
the analysis of analog free thyroxine (FT4) 
being affected by the presence of PFOS, as 
observed in rats highly exposed to PFOS 
(Chang et al. 2007). However, such bias has 
not been observed in a human population 
with typical U.S. serum PFOS concentrations 
but higher PFOA concentrations (Lopez­
Espinosa et al. 2011a).
Published epidemiological findings are 
not consistent (Steenland et al. 2010), have 
generally focused on adults, and have been 
cross­sectional in nature—leaving a gap in 
our understanding of possible PFAA effects in 
children. Whereas associations were reported 
for some PFAAs and thyroid hormones in 
some studies of nonoccupational exposure 
(Dallaire et al. 2009; Kim et al. 2011; Knox 
et al. 2011), others found little or no evidence 
of associations (Bloom et al. 2010; Chan 
et al. 2011; Emmett et al. 2006). Studies in 
occupational settings also reported some sta­
tistically significant associations with thyroid 
hormones, although at high PFAA concen­
trations (Olsen and Zobel 2007; Olsen et al. 
2003). A higher odds ratio (OR) of reported 
thyroid disease was recently associated with 
PFOA or PFOS exposure in the National 
Health and Nutrition Examination Survey 
(NHANES) population (Melzer et al. 2010).
PFOA has been used in the manufac­
ture of fluoropolymers at a chemical plant 
in Parkersburg, West Virginia, since 1951. 
In 2001, a group of residents from the Ohio 
and West Virginia communities in the vicin­
ity of the Washington Works plant filed a 
class­action lawsuit, alleging health damage 
due to contamination of human drinking­
water supplies with PFOA. The settlement 
of this lawsuit led to a baseline survey, called 
the C8 Health Project, conducted during 
2005 and 2006 on residents who lived in six 
contaminated water districts surrounding the 
chemical plant, as described by Frisbee et al. 
(2009). In the Mid­Ohio Valley child popu­
lation 8–18 years of age, PFOA concentra­
tions were markedly higher (Lopez­Espinosa 
et al. 2011b) than in 2005–2006 NHANES 
children 12–19 years of age (median = 23 vs. 
3.8 ng/mL, respectively) (Kato et al. 2011).
Assessment of possible PFAA effects on 
thyroid hormone function in children is of 
special interest for the reasons outlined above. 
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Background: Animal studies suggest that some perfluoroalkyl acids (PFAAs), including 
 perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), and perfluorononanoic acid (PFNA) 
may impair thyroid function. Epidemiological findings, mostly related to adults, are inconsistent.
oBjectives: We investigated whether concentrations of PFAAs were associated with thyroid func-
tion among 10,725 children (1–17 years of age) living near a Teflon manufacturing facility in the 
Mid-Ohio Valley (USA).
Methods: Serum levels of thyroid-stimulating hormone (TSH), total thyroxine (TT4), and PFAAs 
were measured during 2005–2006, and information on diagnosed thyroid disease was collected by 
questionnaire. Modeled in utero PFOA concentrations were based on historical information on 
PFOA releases, environmental distribution, pharmacokinetic modeling, and residential histories. 
We performed multivariate regression analyses.
results: Median concentrations of modeled in utero PFOA and measured serum PFOA, PFOS, 
and PFNA were 12, 29, 20, and 1.5 ng/mL, respectively. The odds ratio for hypothyroidism 
(n = 39) was 1.54 [95% confidence interval (CI): 1.00, 2.37] for an interquartile range (IQR) con-
trast of 13 to 68 ng/mL in serum PFOA measured in 2005–2006. However, an IQR shift in serum 
PFOA was not associated with TSH or TT4 levels in all children combined. IQR shifts in serum 
PFOS (15 to 28 ng/mL) and serum PFNA (1.2 to 2.0 ng/mL) were both associated with a 1.1% 
increase in TT4 in children 1–17 years old (95% CIs: 0.6, 1.5 and 0.7, 1.5 respectively).
conclusions: This is the first large-scale report in children suggesting associations of serum PFOS 
and PFNA with thyroid hormone levels and of serum PFOA and hypothyroidism.
key words: children, PFAA, PFNA, PFOA, PFOS, T4, thyroid disease, thyroid hormones, TSH. 
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Accordingly, we designed the present study to 
estimate associations of thyroid function with 
a) modeled in utero PFOA concentrations and 
b) measured serum PFOA, PFOS, and PFNA 
concentrations collected during 2005–2006 
in children 1–17 years of age from these Ohio 
and West Virginia communities.
Methods
Study population. The C8 Health Project 
enrolled participants between August 2005 
and July 2006. All participants gave written 
informed consent before inclusion: Parents 
or guardians provided consent on behalf of 
children. The London School of Hygiene 
& Tropical Medicine Ethics Committee 
approved this study. The purpose of the Project 
was to collect health data from members of 
the class action lawsuit through questionnaires 
and blood tests, including measurements of 
PFAAs. Individuals were eligible to partici­
pate in the C8 Health Project if they had con­
sumed water for at least 1 year between 1950 
and 2004 from six contaminated water dis­
tricts or private wells in proximity to a Teflon 
manufacturing facility. The C8 Health Project 
collected data on 69,030 people, of whom 
12,476 were 1–17 years of age at enroll­
ment. Participation rates for age groups 5–10, 
11–14, and 15–19 years, and residing in the 
area at the time of the survey, were 77%, 87%, 
and 95%, respectively (Frisbee et al. 2009). 
Of the 12,476 children, 10,725 (86%) had 
serum PFAA and thyroid hormone measure­
ments or information on reported thyroid dis­
eases (from questionnaire responses), and were 
included in the present analyses. Within this 
population, 4,713 children were successfully 
matched to their mothers (also participating in 
the C8 Health Project) (Mondal et al. 2012); 
effects on child thyroid function in relation 
to modeled in utero PFOA exposure was also 
estimated for this subsample.
PFAA determinations. Laboratory analy­
ses of PFAA were conducted by a commer­
cial laboratory (Exygen, State College, PA, 
USA). Samples collected at survey were 
analyzed for 10 PFAAs including PFOA, 
PFOS, and PFNA. The laboratory analyti­
cal methods and quality control procedures 
have been described elsewhere (Frisbee et al. 
2009). Briefly, serum concentrations of PFAA 
were determined using liquid chromatog­
raphy separation with detection by tandem 
mass spectrometry. Estimates of precision 
for PFOA were within ± 10% for multiple 
replicates over the range of 0.5–40 ng/mL, 
with a more precise relative precision meas­
ure of approximately 1% for highly fortified 
(10,000 ng/mL) samples. Relative precision 
estimates for PFOS and PFNA were similar to 
those for PFOA. The detection limit (LOD) 
was 0.5 ng/mL, and observations below the 
LOD were assigned a value of 0.25 ng/mL 
(n = 0, n = 16, and n = 107 in the case of 
PFOA, PFOS, and PFNA, respectively, for 
this study population).
Historical PFOA exposures for all par­
ticipants in the C8 Health Project were esti­
mated through environmental, exposure, and 
pharmaco kinetic modeling in conjunction with 
self­reported residential histories. Information 
on plant operations and chemical releases was 
combined with environmental characteristics 
of the region through a series of linked models 
to estimate air and water concentrations of 
PFOA from 1951 to 2008 (Shin et al. 2011a). 
Based on estimates of individual air and water 
intake rates and linkage of residential geocodes 
for participant address histories to public water 
distribution systems and private wells, yearly 
PFOA serum concentrations were estimated 
for each participant in the C8 Health Project 
(Shin et al. 2011b). Historical individual mod­
eled serum PFOA was calibrated by factors 
derived from comparisons of observed with 
predicted serum concentrations in 2005–2006. 
The ratio of observed to predicted (before cali­
bration) estimates for these mothers showed a 
geometric mean (GM) of 1.36, and the inter­
quartile range (IQR) of these ratios was 0.7 to 
2.2. In utero, modeled exposures for each child 
were estimated as the modeled serum concen­
trations in the mother who had been success­
fully matched to the child, at the time of the 
first trimester of pregnancy (n = 4,713); these 
pregnancies occurred from 1987 to 2005.
Thyroid hormone determination and 
subclinical hypo- and hyperthyroidism. We 
assessed thyroid function by measuring thyroid­
 stimulating hormone (TSH) and total T4 (TT4), 
in serum samples (LabCorp, Inc., Burlington, 
NC, USA). TSH was measured using an electro­
chemiluminescence immunoassay (ECLIA; 
Roche Diagnostics, Indianapolis, IN, USA) with 
an LOD of 0.005 μIU/mL. TT4 was meas ured 
using a cloned enzyme donor immunoassay 
(CEDIA; Roche Diagnostics) with an LOD 
of 0.5 μg/dL. Normal ranges for TSH accord­
ing to the laboratory were 0.7–5.97, 0.6–4.84, 
and 0.45–4.5 μIU/mL for children 1–5, 6–10, 
> 10 years of age, respectively. Normal range for 
TT4 was 4.5–12 μg/dL for all ages. The repro­
ducibility for the analytical methods of TSH 
(n = 60) and TT4 (n = 21) was 7.2% and 9.2%, 
for the lowest concentrations (0.035 μIU/mL 
and 3.7 μg/dL, respectively).
We generated categories of subclinical 
hypothyroidism and hyperthyroidism based 
on the measured thyroid hormone levels, after 
excluding participants who reported any thy­
roid disease and/or medication. Subclinical 
hypo/hyperthyroidism cutoffs are preferably 
based on normal laboratory reference ranges 
of TSH and FT4, but in the absence of FT4 
we used TSH and TT4, as reported previ­
ously (Wu et al. 2006). Based on hormone 
levels, we classified children in the category 
of subclinical hypothyroidism if the TSH 
value was above the upper bound of the 
normal reference range given for the labora­
tory (which varies according to age groups, 
i.e., TSH > 5.97, > 4.84, > 4.5 μIU/mL in 
children < 6, 6–10, > 10 years of age, respec­
tively), whereas TT4 was within its reference 
range (4.5–12 μg/dL). The number of children 
with high TSH (> 10 μIU/mL) and low TT4 
(< 4.5 μg/dL) was too small (n = 8) for sepa­
rate analyses, and these children were included 
in the category of subclinical hypo thyroidism. 
We classified children in the subclinical hyper­
thyroidism category if the TSH value was 
below the lower bound of the normal refer­
ence range given by the laboratory (which var­
ies according to age groups, i.e., TSH < 0.7, 
< 0.6, < 0.45 μIU/mL in children < 6, 6–10, 
> 10 years of age, respectively) and TT4 within 
the normal reference range (4.5–12 μg/dL). 
Children with low TSH (< 0.1 μIU/mL) and 
high TT4 (> 12 μg/dL) (n = 4) were included 
in the subclinical hyperthyroidism category.
Self-reported thyroid disease and medica-
tion. Parents or legal guardians completed a 
questionnaire, including information on diag­
noses for thyroid disease. Respondents were 
asked whether they had ever been told by a 
health­care provider that the child had thyroid 
disease. If the answer was yes, they were asked 
to select between one of these types of thy­
roid diseases: goiter, Hashimoto’s thyroiditis, 
Graves disease, or others. In the last category, 
they were asked to provide the type of thyroid 
disease (most of whom noted hypothyroid­
ism). We considered three classifications of 
thyroid diseases: a) reported diagnosis with 
any thyroid disease; b) reported Hashimoto’s 
thyroiditis or hypothyroidism; and c) a nar­
rower self­reported thyroid disease definition 
formed by combining report of any type of 
thyroid disease diagnosis with reported current 
use of one of the following medications com­
monly used to treat thyroid disease: Armour 
thyroid, Levothroid, Levothyroxine, Levoxil, 
Methimazole, or Synthroid.
Covariates. Covariates available for anal­
ysis included age (years), sex, race/ethnicity 
(non­Hispanic white vs. others), body mass 
index (BMI) expressed as kilograms per meter 
squared and transformed to a z­score based on 
the 2000 U.S. Centers for Disease Control and 
Prevention (CDC) growth charts of BMI­for­
age (CDC EpiInfo 2010), month of sampling, 
average household family income (≤ $10,000, 
$10,001–20,000, $20,001–30,000, $30,001–
40,000, $40,001–50,000, $50,001–60,000, 
$60,001–70,000, > $70,000, or not known), 
ever smoking (yes or no), and ever alcohol 
intake (yes or no).
In models of in utero exposure, for a sub­
sample, we also had information on newborn’s 
birth weight (grams) and gestational age 
(weeks) and maternal weight gain (pounds), 
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smoking habit (yes or no), and alcohol con­
sumption (yes or no) during pregnancy.
Statistical analyses. We conducted a 
regression analysis among participants 1–17 
years of age at survey to assess the relation­
ship between thyroid function and modeled 
in utero PFOA concentrations or measured 
serum PFOA/PFOS/PFNA concentrations in 
samples collected during 2005–2006. Levels 
of TSH and PFAAs showed a non­normal 
distribution and were natural log–transformed 
before inclusion in the models. We used sim­
ple Pearson correlations to describe pairwise 
relationships between thyroid hormones and 
also between PFAAs.
We ran linear regression analyses after 
exclusion of individuals with reported thyroid 
disease and/or thyroid medication, to calcu­
late the regression coefficient (beta) and 95% 
confidence intervals (CIs) for thyroid hor­
mone levels and PFAA quartiles or ln(PFAA) 
concentrations (the later stratified by sex and 
age groups). Adjusted differences in thyroid 
hormone levels between quartile groups of 
PFAA exposure were expressed as percentages 
relative to the lowest exposure quartile, calcu­
lated as the complement of the exponentiated 
regression coefficient {100 × [exp(beta)–1]} 
for TSH and the ratio of beta to the mean 
[(beta/mean) × 100], for TT4. After fitting 
models of ln(PFAA) on ln(TSH) or TT4, 
regression coefficients were transformed to 
represent percent change in TSH or TT4 
associated with the IQR—the 75th compared 
with the 25th percentile for each PFAA expo­
sure estimate. IQRs were calculated for each 
sex/age group. For TSH, this is the exponen­
tiated value of the product of the coefficient 
for the interquartile difference in ln(PFAA). 
For non­log­transformed TT4, we estimated 
the absolute change in TT4 associated with 
one IQR of ln(PFAA) as the coefficient times 
the IQR and expressed this as a percent of 
the mean TT4. We also fit linear regression 
models including other PFAAs. In addition, 
we performed a sensitivity analysis including 
children with untreated thyroid diseases (i.e., 
without reported thyroid medication use), 
but because no major differences were found, 
we did not present these results.
We ran logistic regression models to cal­
culate ORs and 95% CIs for three categories 
of reported disease (any thyroid disease, hypo­
thyroidism, and thyroid disease plus medica­
tion) and for subclinical hypothyroidism or 
hyperthyroidism (based on measured thyroid 
hormone levels) in association with IQR shifts 
in PFAA concentrations. Finally, we assessed 
modeled in utero and measured serum PFOA 
in the same models.
We adjusted final models by child age 
and sex (when not stratified by this variable) 
and month of sampling [because there was a 
trend in measured PFAA during the collection 
year as well as seasonal variations in thyroid 
hormone levels (Maes et al. 1997)]. No other 
variables considered met our operational defi­
nition of confounder because there was < 10% 
change in the PFAA coefficients when includ­
ing or excluding them from the final regression 
models. These included maternal (age, weight 
gain, smoking habit, and alcohol consumption 
during pregnancy) and child (birth weight, 
gestational age, BMI, average household family 
income, race/ethnicity, and smoking habit and 
alcohol intake) variables. For variables with 
missing values (Table 1), the above criterion 
was applied for the subsample of participants 
without missing values. We used the statisti­
cal software package STATA for all statistical 
analyses (STATA Statistical Software, release 
12; StataCorp, College Station, TX, USA). 
Where associations are referred to as statistically 
 significant, this implies a p­value of < 0.05.
Results
Table 1 shows the characteristics of the study 
population. A slight majority of participants 
were boys (52%), and the mean age in the 
population was 11.4 years. Most of the popu­
lation (97.4%) was white, whereas other 
reported race/ethnicity groups were black 
(1.2%), Hispanic (0.2%), Asian (0.1%), 
American Indian (0.2%), and other (0.9%). 
Of the 10,725 children 1–17 years of age in 
this study, 61 individuals (0.6%) reported 
a diagnosis of thyroid disease and 39 of the 
61 reported a diagnosis of hypothyroidism 
(including Hashimoto’s thyroiditis). A total 
Table 1. Study population (n =10,725), Mid-Ohio 
Valley, 2005–2006.
Variable Value
Children  
Sex 
Boys 5,526 (51.5)
Girls 5,199 (48.5)
Birth weight (g) 3,408 ± 523
Gestational age (weeks) 38.9 ± 1.8
Age (years) 11.4 ± 4.1
Race/ethnicity (white) 10,365 (97.4)
BMI (kg/m2) 21.4 ± 5.4
Alcohol consumption 542 (6.4)
Smoking habit 82 (0.77)
Thyroid disease 61 (0.57)
Household income
< $20,000 2,993 (35.4)
$20,000–70,000 4,335 (51.2)
> $70,000 1,137 (13.4)
Mothersa  
Age (years) 26.2 ± 5.4
Weight gain (lbs) 30.2 ± 13.1
Alcohol consumption 19 (1.2)
Smoking habit 418 (18.5)
Values are n (%) or mean ± SD. Missing values were 
not considered for percentage calculation. The per-
cent of missing values in children’s variables was for 
birth weight: 51%, gestational age: 58%, BMI: 8.2%, ever 
alcohol consumption: 21%, and ever smoking: 0.1%, 
household family income at survey: 21%. The percent of 
missing values in maternal variables during pregnancy 
was for weight gain: 60%, alcohol consumption: 68%, 
smoking habit: 53%. 
aDuring pregnancy.
Table 2. TSH, TT4, and PFAA concentrations in children 1–17 years of age, Mid-Ohio Valley, 2005–2006 
[median (IQR)].
Variable All children Boys Girls 
Measured serum TSH levels (µIU/mL)
1–5 years 1.93 (1.43, 2.62) 2.02 (1.49, 2.72) 1.83 (1.38, 2.54)
6–10 years 2.08 (1.52, 2.79) 2.08 (1.54, 2.77) 2.07 (1.50, 2.81)
> 10 years 1.71 (1.22, 2.38) 1.78 (1.28, 2.47) 1.62 (1.15, 2.31)
1–17 years 1.83 (1.31, 2.55) 1.89 (1.36, 2.59) 1.76 (1.26, 2.50)
Measured serum TT4 levels (µg/dL)
1–5 years 7.80 (7.00, 8.70) 7.70 (6.80, 8.60) 8.00 (7.10, 8.80)
6–10 years 7.70 (6.80, 8.60) 7.50 (6.70, 8.40) 7.80 (7.00, 8.70)
> 10 years 7.20 (6.30, 8.20) 7.00 (6.10, 7.90) 7.50 (6.60, 8.50)
1–17 years 7.40 (6.50, 8.40) 7.20 (6.30, 8.10) 7.70 (6.80, 8.60)
Modeled in utero PFOA concentrations (ng/mL)
1–5 years 23.8 (10.1, 57.2) 25.4 (11.0, 63.2) 20.2 (9.35, 53.7)
6–10 years 14.5 (6.39, 44.9) 15.0 (6.67, 47.4) 14.4 (6.21, 41.0)
> 10 years 9.32 (4.61, 27.7) 8.98 (4.63, 25.6) 9.63 (4.61, 26.6)
1–17 years 11.5 (5.36, 37.2) 11.5 (5.46, 38.7) 11.5 (5.27, 35.4)
Measured serum PFOA concentrations (ng/mL)
1–5 years 33.8 (16.1, 83.3) 36.4 (17.9, 87.8) 32.0 (13.7, 78.3)
6–10 years 32.2 (14.3, 77.7) 34.6 (15.1, 78.2) 30.1 (13.7, 73.4)
> 10 years 26.9 (12.2, 62.7) 30.5 (13.6, 72.1) 23.6 (11.1, 52.3)
1–17 years 29.3 (13.1, 67.7) 32.2 (14.2, 74.8) 26.3 (12.1, 60.5)
Measured serum PFOS concentrations (ng/mL)
1–5 years 16.3 (11.3, 24.2) 16.7 (11.4, 24.4) 16.0 (11.2, 23.9)
6–10 years 21.8 (16.0, 30.9) 22.9 (16.8, 32.1) 20.7 (15.2, 29.3)
> 10 years 19.6 (14.4, 27.0) 20.6 (15.4, 28.3) 18.5 (13.4, 25.3)
1–17 years 20.0 (14.5, 27.8) 20.8 (15.3, 29.0) 18.9 (13.7, 26.3)
Measured serum PFNA concentrations (ng/mL)
1–5 years 1.40 (1.10, 1.90) 1.50 (1.10, 1.90) 1.40 (1.10, 1.90)
6–10 years 1.80 (1.30, 2.30) 1.70 (1.40, 2.30) 1.70 (1.30, 2.40)
> 10 years 1.40 (1.10, 1.90) 1.50 (1.20, 1.90) 1.40 (1.10, 1.70)
1–17 years 1.50 (1.20, 2.00)  1.50 (1.20, 2.00)  1.50 (1.10, 1.90)
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of 53 children who reported thyroid disease 
were > 10 years old, and 46 out of 61 were 
girls. Using the stricter definition of reported 
thyroid disease diagnosis plus use of thyroid 
medication, 0.4% of children (n = 40) were 
counted as cases.
Table 2 shows the levels of thyroid hor­
mones and PFAAs in children. The distribu­
tion of TT4 levels was close to normality with 
mean and median values of 7.5 and 7.4 μg/dL, 
respectively. TSH mean and median values 
were 2.1 and 1.8 μIU/mL. TSH was negatively 
correlated with TT4 (r = –0.07, p < 0.001). 
Modeled in utero PFOA concentration had a 
median of 12 (IQR = 5.4, 37) ng/mL. At the 
time of the survey, median measured serum 
PFOA, PFOS, and PFNA concentrations 
were 29 (IQR = 13, 68), 20 (IQR = 15, 28), 
and 1.5 (IQR = 1.2, 2.0) ng/mL, respectively. 
There was a positive correlation between con­
centrations of the PFAAs at the time of the 
survey (PFOA vs. PFOS: r = 0.24; PFOA vs. 
PFNA: r = 0.09; PFOS vs. PFNA: r = 0.41; 
p < 0.001 in all cases), and between modeled 
in utero and at survey PFOA concentrations 
(r = 0.42, p < 0.001).
Associations between quartiles of PFAAs 
and ln(TSH) and TT4 are shown in Table 3, 
where the lowest quartile is the reference 
exposure category. Associations between IQR 
contrasts in ln(PFAAs) are shown in Table 4. 
There was little evidence for an association 
of PFOA with either ln(TSH) or TT4 in 
children 1–17 years of age (Tables 3 and 4). 
However, an IQR contrast of 10 to 57 ng/mL 
for modeled in utero PFOA was associated 
with a 2% increase in TT4 in children up to 
5 years of age (95% CI: 0.1, 3.9), with similar 
but less precise estimates for boys and girls 
separately in this age group. A change in mea­
sured serum PFOA from 16 to 83 ng/mL was 
associated with a 4% drop in TSH in all chil­
dren ≤ 5 years, but the association appeared 
to be limited to girls (Table 4). In children 
≤ 5 years, associations between measured 
serum PFOA and TSH remained significant 
after adjusting for PFOS (–5.7% change; 95% 
CI: –9.8, –1.4) and PFNA (–4.7% change; 
95% CI: –8.9, –0.4).
Associations between PFOS or PFNA and 
TT4 were found in children 1–17 years of age 
(Tables 3 and 4). Interquartile contrasts of 15 
to 28 ng/mL in PFOS and 1.2 to 2.0 ng/mL 
in PFNA were both associated with a 1.1% 
increase in TT4 (95% CIs: 0.6, 1.5 and 0.7, 
1.5, respectively). The association was evident 
in both girls and boys 10–17 years of age in 
the case of PFOS and for PFNA associations 
overall were significant for both boys and girls 
(Table 4). In addition, associations between 
PFOS or PFNA and TT4 were similar after 
adjustment by other PFAAs percent change 
for PFOS adjusted by PFNA: 0.7, 95% CI: 
0.2, 1.2; or PFOA: 1.1, 95% CI: 0.6, 1.6; 
percent change for PFNA adjusted by PFOS: 
Table 3. Change in thyroid hormone levels by PFAA quartiles in children 1–17 years of age, Mid-Ohio 
Valley, 2005–2006.
Children [percent change (95%CI)]
PFAAs (ng/mL) TSH (μIU/mL) TT4 (μg/dL) 
Modeled in utero PFOA concentrations
Q1: 0.05–5.4 Reference
Q2: 5.5–11.6 0.9 (–3.3, 5.3) 0.1 (–1.4, 1.6)
Q3: 11.7–38.4 –0.2 (–4.5, 4.2) –0.6 (–2.1, 1.0)
Q4: 38.5–3,987 –1.1 (–5.3, 3.4) –0.1 (–1.7, 1.4)
Measured serum PFOA concentrations
Q1: 0.7–13 Reference
Q2: 13.1–29.2 1.0 (–1.9, 4.0) 0.2 (–0.8, 1.2)
Q3: 29.3–67.6 1.0 (–2.0, 4.1) 0.8 (–0.3, 1.9)
Q4: 67.7–2,071 2.4 (–0.6, 5.5) 0.3 (–0.8, 1.3)
Measured serum PFOS concentrations
Q1: 0.25–14.4 Reference
Q2: 14.5–19.9 0.3 (–2.6, 3.2) 0.8 (–0.3, 1.8)
Q3: 20.0–27.7 –1.3 (–4.2, 1.7) 0.9 (–0.2, 1.9)
Q4: 27.8–202 3.1 (0.0, 6.2) 2.3 (1.2, 3.3)
Measured serum PFNA concentrations
Q1: 0.25–1.1 Reference
Q2: 1.2–1.4 0.4 (–2.6, 3.5) 0.8 (–0.3, 1.8)
Q3: 1.5–1.9 –0.3 (–3.2, 2.6) 1.7 (0.7, 2.8)
Q4: 2.0–39.8 1.5 (–1.6, 4.6) 2.7 (1.7, 3.8)
TSH was natural log-transformed. Adjusted differences in thyroid hormone levels between quartile (Q) groups of PFAA 
exposure were expressed as percentages relative to the lowest exposure quartile, calculated from the exponentiated 
regression coefficient for TSH and from the ratio of beta to the mean for TT4.
Table 4. Change in thyroid hormone levels associated with IQR shifts in PFAAs in children 1–17 years of age, Mid-Ohio Valley, 2005–2006 [percent change (95%CI)].
All childrenb  Boysc Girlsc
PFAA na TSH (μIU/mL) TT4 (μg/dL) TSH (μIU/mL) TT4 (μg/dL) TSH (μIU/mL) TT4 (μg/dL) 
Modeled in utero PFOA concentrations
1–5 years 523 –3.4 (–8.8, 2.4) 2.0 (0.1, 3.9) –1.0 (–9.0, 7.6) 1.7 (–1.2, 4.6) –5.8 (–13.4, 2.5) 2.1 (–0.5, 4.8)
6–10 years 1,432 –1.5 (–4.9, 2.1) 0.9 (–0.3, 2.1) –2.6 (–7.4, 2.4) 0.5 (–1.3, 2.3) 0.2 (–5.1, 4.9) 1.3 (–0.4, 3.0)
> 10 years 2,758 0.1 (–2.2, 2.5) –0.7 (–1.5, 0.2) 0.2 (–2.8, 3.3) –0.7 (–1.8, 0.4) –0.1 (–3.7, 3.7) –0.8 (–2.2, 0.5)
1–17 years 4,713 –0.5 (–2.4, 1.5) –0.1 (–0.8, 0.6) –0.3 (–3.0, 2.5) –0.3 (–1.3, 0.7) –0.5 (–3.4, 2.5) –0.1 (–1.1, 1.0)
Measured serum PFOA concentrations
1–5 years 1,078 –4.3 (–8.2, –0.3) 0.7 (–0.7, 2.1) –1.1 (–6.6, 4.7) 1.3 (–0.7, 3.3) –7.7 (–13.2, –1.7) –0.1 (–2.2, 2.0)
6–10 years 3,132 0.5 (–2.0, 3.1) 0.9 (0.0, 1.8) –1.1 (–4.4, 2.3) 0.1 (–1.1, 1.3) 2.2 (–1.7, 6.3) 1.9 (0.6, 3.2)
> 10 years 6,447 2.0 (–0.1, 4.1) –0.3 (–1.1, 0.4) 1.6 (–1.1, 4.3) 0.5 (–0.5, 1.4) 2.4 (–0.7, 5.7) –0.9 (–2.0, 0.2)
1–17 years 10,657 1.0 (–0.5, 2.7) 0.1 (–0.5, 0.6) 0.7 (–1.3, 2.7) 0.4 (–0.3, 1.1) 1.3 (–1.0, 3.8) 0.0 (–0.8, 0.7)
Measured serum PFOS concentrations
1–5 years 1,078 3.1 (–0.9, 7.3) 0.8 (–0.6, 2.2) 1.4 (–4.3, 7.5) 0.4 (–1.7, 2.5) 4.7 (–0.9, 10.5) 1.2 (–0.6, 3.0)
6–10 years 3,132 0.0 (–2.2, 2.3) 0.9 (0.2, 1.7) –1.7 (–4.5, 1.2) 0.4 (–0.7, 1.4) 2.1 (–1.7, 5.7) 1.5 (0.4, 2.7)
> 10 years 6,447 0.9 (–0.8, 2.7) 1.2 (0.6, 1.9) 1.1 (–1.0, 3.2) 1.2 (0.5, 2.0) 0.8 (–1.9, 3.5) 1.1 (0.1, 2.0)
1–17 years 10,657 1.0 (–0.3, 2.3) 1.1 (0.6, 1.5) 0.4 (–1.2, 2.1) 0.9 (0.3, 1.5) 1.6 (–0.5, 3.6) 1.2 (0.5, 1.9)
Measured serum PFNA concentrations
1–5 years 1,078 0.2 (–3.5, 4.1) 1.1 (–0.2, 2.4) –0.7 (–6.0, 4.8) 1.1 (–0.8, 3.0) 1.5 (–3.8, 7.1) 1.1 (–0.7, 2.9)
6–10 years 3,132 0.0 (–2.1, 2.1) 1.0 (0.3, 1.7) –0.9 (–3.3, 1.6) 0.5 (–0.4, 1.4) 1.0 (–2.4, 4.4) 1.4 (0.3, 2.5)
> 10 years 6,447 1.1 (–0.5, 2.8) 1.3 (0.7, 1.9) 2.0 (0.0, 4.0) 1.9 (1.2, 2.6) 0.2 (–2.0, 2.4) 0.5 (–0.3, 1.3)
1–17 years 10,657 0.8 (–0.4, 2.0) 1.1 (0.7, 1.5) 1.0 (–0.7, 2.6) 1.4 (0.9, 2.0) 0.5 (–1.4, 2.5) 0.9 (0.2, 1.5)
PFAAs and TSH were natural log-transformed. Change in TSH calculated from the exponentiated regression coefficient and change in TT4 as a percent of the mean. 
aNumber of children with PFAA measurements after excluding those who reported thyroid disease and/or thyroid medication (also excluded from models): boys, n = 5,526; girls, 
n = 5,199. Models adjusted by sexb, ageb,c, and month of samplingb,c.
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0.8, 95% CI: 0.4, 1.3; or PFOA: 1.1, 95% 
CI: 0.6, 1.5). We did not find evidence of 
associations between serum PFOS or PFNA 
and TSH.
The OR for thyroid disease (n = 61) was 
1.44 (95% CI: 1.02, 2.03) (Table 5). Most 
of the children with thyroid disease were 
reported to have hypothyroidism (n = 39; 
OR = 1.54; 95% CI: 1.00, 2.37). The asso­
ciation was similar for the strictest definition 
of reported thyroid disease plus use of thy­
roid medication (OR = 1.61; 95% CI: 1.07, 
2.51). Associations were similar for modeled 
estimates of in utero PFOA concentrations, 
although CIs were a little wider (Table 5). 
We also performed analyses including both 
modeled in utero and measured PFOA in 
the same model, and in both cases ORs were 
attenuated and CIs were wider (OR = 1.29; 
95% CI: 0.87, 1.92; and OR = 1.27; 95% 
CI: 0.74, 2.19 for thyroid disease vs. PFOA 
modeled in utero or at survey, respectively). 
We did not find associations between concen­
trations of any of the PFAAs and subclinical 
hypo/hyperthyroidism (Table 5).
Discussion
To the best of our knowledge, this is the first 
large­scale report of an association between 
PFAAs in serum and thyroid function impair­
ment in children 1–17 years of age. In a 
group of 10,725 children from the Mid­Ohio 
Valley, measured serum PFOA concentra­
tions in 2005–2006 were positively associated 
with thyroid disease (mostly hypothyroidism). 
In addition, serum concentrations of PFOS 
and PFNA, but not PFOA, were positively 
associated with TT4 levels in children 1–17 
years of age.
Serum PFOS and PFNA concentrations 
were associated with slightly higher levels 
of TT4 in children 1–17 years of age, but 
were not positively associated with subclinical 
hyperthyroidism. PFOA was not associated 
with TSH or TT4 in all children combined, 
though subgroup analyses suggested possible 
associations with PFOA measured at survey 
and modeled in utero, in children ≤ 5 years. 
However, given the lack of effect in the other 
age groups, this may be a chance finding. 
Previous literature on child thyroid func­
tion and PFAA exposure is limited. A recent 
study in Korea (n = 29) reported a positive 
association between maternal serum PFOA 
(median = 1.46 ng/mL) concentrations and 
cord serum TSH levels. No association was 
found between PFOA, PFOS, or PFNA and 
T4 (Kim et al. 2011). Another small study 
of 15 Japanese mother–child pairs reported 
no apparent correlation between maternal 
blood PFOS (median = 8.1 ng/mL) concen­
trations and neonatal blood TSH or FT4 
(Inoue et al. 2004). In agreement with our 
results, a recently published study of 52,296 
adults from the C8 Health Project found a 
positive association between serum PFOS and 
TT4. They also found a positive association 
between serum PFOA and TT4 in women 
of all ages, and men > 50 years of age (Knox 
et al. 2011). In addition, a positive associ­
ation was reported between plasma PFOS 
(GM = 18.3 ng/mL) and FT4 levels and 
inverse with TSH in environmentally exposed 
adults (n = 621) from Nunavik, Quebec, 
Canada (Dallaire et al. 2009). On the con­
trary, a modest inverse association between 
serum PFOA (median = 1.1 μg/mL) and FT4 
but not TT4 or TSH levels was reported in 
an occupational study among 506 employees 
in one Belgian and two American factories 
(Olsen and Zobel 2007). Some adult studies 
have not found associations between PFAA 
exposures and thyroid level alteration, includ­
ing a study of Canadian pregnant women 
with hypothyroxinemia (n = 96; PFOA and 
PFOS medians = 3.9 and 15.5 nmol/L) 
whose serum PFAA concentrations were com­
parable to matched controls (n = 175; PFOA 
and PFOS medians = 3.6 and 16.4 nmol/L) 
(Chan et al. 2011). There was no evidence 
of an association between elevated serum 
PFOA (median = 354 ng/mL) and TSH lev­
els in residents (n = 371) from the same area 
as the present study (Emmett et al. 2006). 
In a small study (n = 31) of anglers from 
New York State, no association was reported 
between PFOA, PFOS, or PFNA concentra­
tions (GM = 1.3, 19.6, and 0.79 ng/mL) and 
serum TSH or FT4 levels (Bloom et al. 2010).
Altered thyroid hormone levels follow­
ing exposure to PFAAs have also been found 
in experimental animal studies where pre­ 
and postnatal long­term exposure to PFOS 
decreased serum levels of TT4 and FT4 in 
pregnant dams and pups, without a concomi­
tant rise in TSH (Lau et al. 2007). PFNA 
exposure did not alter TT4 levels in zebrafish 
juveniles treated with PFNA until maturity 
(Liu et al. 2011). In adult monkeys, PFOA 
exposure during 6 months, which led to 
serum levels up to 158 μg/mL, did not alter 
TT4 or TSH (Butenhoff et al. 2002).
We found higher odds of reporting thy­
roid disease (mostly hypothyroidism) with 
increased measured PFOA concentrations, 
even when we restricted cases to children with 
reported disease plus use of thyroid medica­
tion. However, PFOA concentrations were 
not associated with subclinical hypo/hyper­
thyroidism based on individual hormone 
levels or thyroid hormone levels (as continu­
ous variables) in children 1–17 years of age. 
Therefore, the association between reported 
thyroid disease and PFOA exposure should 
be considered with caution. Nevertheless, 
these results are comparable to a cross­
 sectional analysis of PFOA/PFOS concentra­
tions and reported thyroid disease in adults in 
NHANES for 1999–2000, 2003–2004, and 
2005–2006 (n = 3,966). An OR of 2.2 (95% 
CI: 1.4, 3.7) was estimated for thyroid disease 
in association with the highest versus first and 
second quartiles of serum PFOA in females 
(mean = 3.77 ng/mL), and a similar associa­
tion with serum PFOS (mean = 25.1 ng/mL) 
was reported for males (OR = 2.7; 95% CI: 
1.0, 7.0) (Melzer et al. 2010).
The main strengths of the present study 
are the large sample size and the data for both 
measured and modeled in utero PFOA con­
centrations. A further strength is the high 
rate of participation, diminishing concern 
about potential selection biases. It is believed 
that this population is representative, given 
the high participation rates in the C8 Health 
Project, of all those children who drank con­
taminated water in the Mid­Ohio Valley. 
Moreover, we were able to adjust for a num­
ber of potential confounders.
The mostly cross­sectional design of the 
present study is a major limitation because the 
single measurements preclude determination of 
the time sequence between PFAA exposure and 
outcome, and some associations may have been 
attributable to chance or uncontrolled sources 
of bias. One further limitation is the absence 
of measurements of child triiodothyronine and 
FT4 levels, which would have yielded more 
comprehensive information concerning the 
Table 5. ORs (95% CIs) of thyroid disease for IQR shift in PFAA concentrations in children 1–17 years of age, Mid-Ohio Valley, 2005–2006.
Reported Subclinical
Thyroid disease Hypothyroidism Hypothyroidisma Hyperthyroidisma
PFAA n OR (95% CI) n OR (95% CI) n OR (95% CI) n OR (95% CI)
Modeled in utero PFOA 27 1.47 (0.95, 2.27) 20 1.61 (0.96, 2. 63) 155 0.94 (0.76, 1.16) 31 1.10 (0. 69, 1.74)
Measured serum PFOA 61 1.44 (1.02, 2.03) 39 1.54 (1.00, 2.37) 365 0.98 (0.86, 1.15) 78 0.81 (0.58, 1.15)
Measured serum PFOS 61 0.8 (0.62, 1.08) 39 0.91 (0.63, 1,31) 365 0.99 (0.86, 1.13) 78 0.80 (0.62, 1.02)
Measured serum PFNA 61 1.05 (0.78, 1.41) 39 1.11 (0.77, 1.60) 365 0.99 (0.88, 1.12) 78 0.78 (0.61, 1.01)
PFAAs were natural log-transformed. Models were adjusted by age and sex. 
aBased on hormonal levels at survey after excluding people who self-reported thyroid disease and/or thyroid medication.
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child’s thyroid regulatory system. Another 
limitation is the reliance on recall for thyroid 
diagnosis, although we also investigated a more 
stringent case definition of report plus medica­
tion use and obtained similar results. However, 
the prevalence of hypothyroidism reported in 
our study population (0.4%) was higher than 
the range (0.04–0.14%) of the estimated preva­
lence in several children and adolescent popula­
tions (Hunter et al. 2000). Based on TSH and 
TT4 levels, the prevalence of subclinical hypo­
thyroidism in the 1988–1994 NHANES pop­
ulation (Wu et al. 2006) was lower than that of 
the present study (1.7% vs. 2.9%, respectively, 
in children > 12 years of age), whereas subclini­
cal hyperthyroidism was more prevalent (2.3% 
vs. 1.2% in children > 12 years). 
Conclusions
In summary, this is the first large­scale report 
on thyroid hormone function and PFAA 
concentrations among children 1–17 years 
of age. Results suggest that serum PFOS and 
PFNA concentrations are associated with 
thyroid hormone levels, and serum PFOA 
concentrations are associated with reported 
hypothyroidism. However, further studies 
to understand the effect of pre­ or postnatal 
exposure to PFAAs on thyroid hormones in 
children are warranted.
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